儿童急性哮喘发作标准一线治疗加用静脉氨茶碱的系统综述与Meta分析
该系统综述与Meta分析纳入9项随机对照试验共466名儿童和青少年急性哮喘发作患者,评估标准一线治疗加用静脉氨茶碱的安全性和有效性。结果显示氨茶碱组在哮喘严重度评分、住院率、PICU入住率、插管率和住院时长方面与对照组无显著差异,但呕吐和恶心发生率显著更高。
要点
- 静脉氨茶碱未显著改善治疗后哮喘严重度评分、住院率、PICU入住率、插管率或住院时长。
- 氨茶碱组呕吐(RR=3.52)和恶心(RR=4.92)发生率显著高于对照组。
- 仅一项研究显示氨茶碱组肺功能改善,其他研究未见差异。
核心结论
- 本综述显示静脉氨茶碱在大多数预防插管严重度参数上获益证据有限,但降低插管率和改善肺功能值得更多关注。
研究设计与样本
- 系统综述与Meta分析,检索MEDLINE、Embase、CINAHL、Web of Science和Cochrane CENTRAL从1966年至2024年5月,仅纳入随机对照试验,共纳入9项研究466名参与者。
主要发现
- 治疗后哮喘严重度评分无显著差异(MD=0.13,95%CI -0.79至1.06,I2=0%)。
- 住院率无显著差异(RR=0.66,95%CI 0.27至1.59,I2=0%)。
- PICU入住率无显著差异(RR=0.73,95%CI 0.51至1.05,I2=0%)。
- 插管率无显著差异(RR=0.09,95%CI 0.01至1.64,p=0.1)。
- 住院时长无显著差异(MD=-3.62,95%CI -13.05至5.82,I2=31%)。
临床怎么用
- 在儿童和青少年急性哮喘发作中,标准一线治疗加用静脉氨茶碱对多数严重度参数无显著获益,且呕吐和恶心风险增加。
局限性
- 纳入研究数量较少(9项),总样本量466人,证据有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The role of intravenous aminophylline in acute asthma in childhood is unclear. OBJECTIVES: To assess the safety and efficacy of intravenous aminophylline for asthma in children. METHODS: From 1966 to May 2024, we searched MEDLINE, Embase, CINAHL, Web of Science and the Cochrane Central Register of Controlled Trials. We included only randomised controlled trials testing standard treatment in combination with aminophylline and followed the international guidelines for conducting systematic reviews. The outcomes measured were morbidity, escalation of care, length of hospital stay, adverse events, mortality and lung functions. We used the random-effects model for data analysis and the fixed-effects model to evaluate heterogeneity. RESULTS: Nine studies (466 participants) fulfilled our a priori eligibility criteria. No significant difference was found in post-treatment asthma severity score (mean difference (MD)=0.13, 95% CI -0.79 to 1.06, I2=0 %), hospitalisation rate (risk ratio (RR)=0.66, 95% CI 0.27 to 1.59, I2=0%), paediatric intensive care unit admission (RR=0.73, 95% CI 0.51 to 1.05, I2=0%), intubation rate (RR=0.09, 95% CI 0.01 to 1.64, p=0.1) or length of hospital stay (MD=-3.62, 95% CI -13.05 to 5.82, I2=31%). Emesis (RR=3.52, 95% CI 2.04 to 6.06, I2=0%) and nausea (RR=4.92, 95% CI 2.41 to 10.06, I2=0%) occurred more in the aminophylline group. One study showed improved lung function in the aminophylline group, while others showed no difference. CONCLUSION: This review showed limited evidence of the benefit of intravenous aminophylline in managing asthma in most preventilation severity parameters. However, lowering the intubation rate and improving lung function deserve more attention. PROSPERO REGISTRATION NUMBER: CRD42023405234.
引用
- Mudawi K, Hamud A, Powell C, et al. Use of intravenous aminophylline in addition to the standard first-line treatment in children and adolescents with an acute asthma exacerbation: a systematic review and meta-analysis of randomised controlled trials. Arch Dis Child. 2025. PMID: 40562458. doi:10.1136/archdischild-2024-327492
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。